Media.Player

Histone Deacetylase Inhibitors for Prevention of Secondary Cataract

Detailed Technology Description

None

Others

*Abstract

Non-Confidential Abstract of InventionUM Disclosure No. 13UMC013Histone Deacetylase Inhibitors for Prevention of Secondary CataractCataracts are the world’s leading cause of blindness. Although cataract surgery is an effective treatment for cataracts; secondary cataracts, also called Posterior Subcapsular Opacification (PCO), often develop within 3-5 years of cataract surgery, with rates documented to be as high as 15-50% in different studies. Current YAG laser treatment for PCO is associated with potential problems including optic damage, retinal detachment, etc. Researchers at the University of Missouri have developed a new use for commercially available FDA-approved drugs in preventing PCO formation. The in vitro studies show that this approach prevents the molecular changes similar to those that occur during secondary cataract formation. Successful development of these drugs to control PCO will significantly impact cataract treatment.POTENTIAL AREAS OF APPLICATION:• Secondary cataract prevention• Drug formulation consisting of HDAC inhibitorsMAIN ADVANTAGES OF INVENTION:• Reduced cost for patients, healthcare facilities, and insurance companies• Utilizes already approved FDA drugs• Preventative method• 1.5 Million cataract surgeries annually in the U.S.STAGE OF DEVELOPMENT:• Pre-clinicalPATENT STATUS:• In preparationCONTACT INFO:Paul Hippenmeyer, Sr. Licensing & Business Development AssociateOffice of Technology Management and Industry Relations Email: hippenmeyerp@missouri.edu Phone: 573-882-0470

*Principal Investigator

Name: K. SHARMA, Professor

Department:

Name: Lixing Reneker, Associate Professor of Ophthalmology & Biochemistry Medicine

Department:

Name: Santhoshkumar Puttur, Assistant Research Professor

Department:

Name: Leike Xie, Research Associate

Department:

Country/Region

USA